Your browser is no longer supported. Please, upgrade your browser.
BMY Bristol-Myers Squibb Company daily Stock Chart
Bristol-Myers Squibb Company
IndexS&P 500 P/E24.52 EPS (ttm)2.01 Insider Own0.10% Shs Outstand1.88B Perf Week-12.94%
Market Cap92.74B Forward P/E16.58 EPS next Y2.97 Insider Trans-2.60% Shs Float1.67B Perf Month-16.60%
Income3.37B PEG1.47 EPS next Q0.66 Inst Own71.20% Short Float0.75% Perf Quarter-0.63%
Sales18.47B P/S5.02 EPS this Y-22.30% Inst Trans0.04% Short Ratio1.25 Perf Half Y-33.91%
Book/sh9.34 P/B5.27 EPS next Y3.96% ROA10.30% Target Price62.34 Perf Year-20.07%
Cash/sh2.95 P/C16.68 EPS next 5Y16.74% ROE22.70% 52W Range48.71 - 76.09 Perf YTD-15.20%
Dividend1.56 P/FCF- EPS past 5Y-12.20% ROI4.60% 52W High-35.30% Beta1.02
Dividend %3.17% Quick Ratio1.30 Sales past 5Y-3.20% Gross Margin75.70% 52W Low1.07% ATR1.45
Employees25000 Current Ratio1.50 Sales Q/Q21.00% Oper. Margin24.70% RSI (14)18.17 Volatility2.05% 1.65%
OptionableYes Debt/Eq0.44 EPS Q/Q71.10% Profit Margin18.20% Rel Volume7.66 Prev Close55.49
ShortableYes LT Debt/Eq0.37 EarningsJan 26 BMO Payout75.40% Avg Volume10.05M Price49.23
Recom2.30 SMA20-15.40% SMA50-13.53% SMA200-20.71% Volume76,979,653 Change-11.28%
Dec-19-16Upgrade Jefferies Hold → Buy
Oct-28-16Reiterated Deutsche Bank Hold $59 → $52
Sep-09-16Reiterated Barclays Equal Weight $75 → $65
Aug-11-16Downgrade Berenberg Buy → Hold
Aug-08-16Reiterated Deutsche Bank Hold $68 → $62
Aug-08-16Downgrade Credit Suisse Outperform → Neutral $63
Aug-05-16Downgrade Morgan Stanley Overweight → Equal-Weight
May-23-16Initiated Hilliard Lyons Neutral
Apr-29-16Reiterated UBS Buy $73 → $80
Apr-29-16Reiterated Barclays Equal Weight $70 → $75
Apr-06-16Initiated Societe Generale Sell $48
Jan-22-16Upgrade Berenberg Hold → Buy
Dec-02-15Upgrade Guggenheim Neutral → Buy
Dec-01-15Reiterated Barclays Equal Weight $55 → $70
Aug-24-15Upgrade Piper Jaffray Underweight → Neutral
Jun-17-15Initiated Piper Jaffray Underweight $60
May-14-15Initiated Berenberg Hold $70
Apr-21-15Upgrade Morgan Stanley Equal-Weight → Overweight $60 → $80
Feb-27-15Reiterated Argus Buy $70 → $78
Jan-12-15Reiterated Argus Buy $62 → $70
Jan-20-17 06:52PM  Why Rite Aid, Bristol-Myers Squibb, and TransDigm Group Slumped Today at Motley Fool -11.28%
05:09PM  The Biggest Loser: Bristol-Myers Sinks 11% at
04:55PM  [$$] Merck Settles With Bristol-Meyers, Ono Over Cancer-Drug Patent at The Wall Street Journal
04:54PM  Biggest stock winners (including a fracking company) and losers on Donald Trumps first day; Dow, S&P 500, Nasdaq all up at
04:53PM  Bristol-Myers lung cancer delay slams shares, keeps Merck in lead
04:29PM  Jim Cramer on Bristol-Myers' Opdivo/Yervoy Combo: 'That Story Was Taken Away From Us'
04:23PM  Merck, Bristol-Myers agree to settle Keytruda patent suit
04:16PM  Merck will pay $625 million and royalties to settle Keytruda patent litigation with Bristol-Myers Squibb and Ono Pharma at MarketWatch
04:15PM  Bristol-Myers Dives On Opdivo Setback, Will Get Keytruda Royalties
04:04PM  Bristol-Myers, Target Sink into Fridays 52-Week Low Club
04:01PM  Bristol-Myers Squibb and Ono Pharmaceutical Company Enter Settlement and License Agreement with Merck to Resolve PD-1 Antibody Patent Litigation Business Wire
03:23PM  Dow Industrials Take Lead As Trump Sworn In; Nvidia Sits Out Chip Rally
02:01PM  Bristol's Opdivo Dependence Now Looks Dicey at Bloomberg
01:31PM  Stocks Fall Off Highs; Trump Sworn In As President
12:51PM  Why Bristol-Myers Squibb Co Stock Is Slipping Today at Motley Fool
12:32PM  Bristol-Myers shares drop after company says it will not seek fast-track drug approval at CNBC
12:14PM  Bristol-Myers Squibb: There Goes Any Chance for Upside at
11:48AM  Ready to Trade Bristol-Myers Squibb, Bank of America, CSX? Here's What to Know
11:11AM  Bristol-Myers tight-lipped pass on accelerated lung cancer drug approval leaves field wide open for Merck at MarketWatch
10:29AM  Stocks Up Nicely In Early Trade; Apple Shrugs Off China Trade Talk
10:17AM  [$$] Bristol-Myers shares slide on immunotherapy setback at Financial Times
10:07AM  Stock market rises as Trumps inauguration holds focus at MarketWatch
09:24AM  Bristol-Myers to Not Seek Accelerated Approval for Opdivo+Yervoy
08:55AM  Setback for Bristol-Myers on Lung Cancer Treatment Drugs at TheStreet
08:17AM  Bristol-Myers Squibb, Where Art Thou? Not in First-Line Lung Cancer Immunotherapy, Sadly
08:06AM  Stock Futures Steer Higher; Merck, Skyworks, Emerge Energy Climb
07:48AM  Bristol-Myers Squibb stock sinks 7.2% after it says it won't pursue accelerated approval for lung cancer combination treatment at MarketWatch
07:38AM  Why Johnson & Johnsons 4Q16 Revenues Could Grow
Jan-19-17 07:33PM  Bristol-Myers Falls Further Behind Merck in Lung Cancer Race at Bloomberg
06:49PM  Bristol-Myers won't seek accelerated Opdivo lung cancer approval Reuters
06:30PM  Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer Business Wire
03:08PM  U.S. top court to hear Bristol-Myers out-of-state injury appeal Reuters
09:00AM  Opdivo (nivolumab) Demonstrated Efficacy and Improved Survival in Patients with Previously Treated Advanced Gastric Cancer in a Randomized Phase 3 Study Business Wire
08:39AM  Bristol-Myers (BMY) Q4 Earnings: Will the Stock Disappoint?
Jan-18-17 12:12PM  Trump health pick Price defends investments, Obamacare replacement Reuters
08:30AM  AstraZeneca Offers Update on Immuno-Oncology Program
06:00AM  Trump's health pick set to defend investments at U.S. Senate hearing Reuters
Jan-17-17 04:32PM  FDA Track Record Bodes Well For Merck Keytruda Plus Chemo: Leerink
09:59AM  Why Bristol-Myers Squibb May Be a Merger Target Soon
Jan-16-17 10:14AM  These 5 Drug Patents Will Expire in 2017 at Investopedia
Jan-13-17 10:45AM  Bristol-Myers Squibb Co. Value Analysis (NYSE:BMY) : January 13, 2017
09:06AM  Mylans Recent Commercial and Product Developments
Jan-12-17 05:10PM  Trumps HHS nominee has promised to divest from these Mass. companies at
04:04PM  Bristol-Myers Threatens Merck's 'Head Start' In Lung Cancer: Analyst
02:00PM  Eli Lilly Rebounds On Chemo-Drug Patent Win Vs. Generic Teva
09:55AM  3 Charts Every Bristol-Myers Squibb Shareholder Needs to See at Motley Fool
09:54AM  Merck: News So Good Three Analysts Had to Upgrade It at
07:57AM  Bristol-Myers Squibb Co. breached its 50 day moving average in a Bearish Manner : BMY-US : January 12, 2017
07:35AM  Trump criticism leads to falling stock prices at these Tampa employers at
Jan-11-17 04:33PM  Bristol-Myers and AstraZeneca Take Beatings -5.30%
01:59PM  Trump's Comments Slam Drug Stocks at The Wall Street Journal
01:03PM  2 Stocks For a Trump-ed Up Pharma Market at
12:28PM  Merck Lung-Cancer Drug May Get OK For Large Patient Population
10:29AM  Merck: One Giant Leap at
10:10AM  Merck boosts Dow, Amazon prime members get a new perk, ADM to buy pet food producer
09:52AM  Merck leapfrogs rivals in lung cancer drug combination race Reuters
Jan-10-17 08:23AM  Here's a Biotech IPO You'll Want to Watch at Motley Fool
Jan-09-17 08:11AM  Bristol-Myers, GeneCentric Tie Up for Opdivo Biomarker Study
Jan-08-17 07:25AM  5 Tough Questions for Bristol-Myers Squibb's CEO at Motley Fool
Jan-06-17 06:16PM  Cramer's game plan: Banks will be in hog heaven next week at CNBC
11:01AM  It Was CheckMate for Bristol-Myers Squibb Company in 2016 at Motley Fool
09:42AM  2 Big Reasons Merck & Co., Inc. Stock Surged 11% in 2016 at Motley Fool
08:17AM  Bristol-Myers, J&J Ink Immunotherapy Research Collaboration
08:15AM  Blog Coverage Five Prime Announced Extension of Collaboration Agreement by Bristol-Myers Squibb Accesswire
07:24AM  Pharma Stock Roundup: PCSK9 Inhibitor Praluent in News, Allergan's Preliminary 2017 View
06:59AM  Bristol-Myers Squibb and GeneCentric Diagnostics Announce Exploratory Biomarker Research Collaboration Business Wire
Jan-05-17 05:59PM  Final Trade: BMY, FXI & more
03:09PM  Crystal Ball Gazing: Biotech Predictions For 2017 at Forbes
12:36PM  Senate Dems, D.C. Watchdog Call for Investigation Into Trump HHS Pick Tom Price's Stock Portfolio
09:43AM  The 4 Building Blocks That Pushed Exelixis, Inc. Higher by 164% in 2016 at Motley Fool
09:10AM  The Scariest Thing About Bristol-Myers Squibb's Dividend at Motley Fool
08:13AM  Bristol-Myers Extends Deal with Five Prime Therapeutics
06:59AM  Bristol-Myers Squibb Announces Immunotherapy Clinical Collaboration with Janssen to Evaluate Opdivo (nivolumab) in Combination with Darzalex (daratumumab) Business Wire
Jan-04-17 05:16PM  Deutsche Bank to pay $95 mln to end U.S. tax fraud case Reuters
04:05PM  Five Prime Therapeutics and Bristol-Myers Squibb Extend Research Term in Collaboration to Discover Novel Immuno-Oncology Therapies for Three Immune Checkpoint Pathways GlobeNewswire
09:01AM  Bristol-Myers Trades Ex-Dividend Wednesday at Investopedia
06:25AM  4 Reasons Why Pfizer (PFE) Could be a Great Pick in 2017
Jan-03-17 09:18AM  Bristol-Myers Squibb to Present at J.P. Morgan Healthcare Conference Business Wire
Jan-01-17 11:09AM  3 Biggest Risks for Bristol-Myers Squibb in 2017 at Motley Fool
Dec-30-16 06:05PM  What Factors Are Contributing to Gilead Sciences Growth?
09:27AM  ARIAD Stock Beats Industry in 2016, Iclusig Sales Strong
09:07AM  How GlaxoSmithKlines Pharmaceuticals Segment Has Performed
Dec-29-16 09:00AM  Bristol-Myers Squibb to Take Part at the Goldman Sachs Healthcare CEOs Unscripted: A View from the Top Business Wire
07:36AM  Will Keytrudas Position Strengthen in the Lung Cancer Market?
02:00AM  Bristol-Myers, Tiffany among NYC companies lauded for environmental, social values at
Dec-28-16 07:48AM  Bristol-Myers Squibb draws upside bet
Dec-27-16 09:07AM  Portola Betrixaban Accepted for Review in U.S. & EU, Stock Up
Dec-24-16 03:37PM  If You're in Your 40s, Consider Buying These Stocks at Motley Fool
Dec-23-16 05:35PM  Why Portola Pharmaceuticals Inc Stock Surged Higher Today at Motley Fool
02:32PM  Gilead Sciences, Inc. (GILD) Is A Hail Mary: 3 Better Stocks To Consider at Insider Monkey
12:41PM  Something Strange Is Going On With Oral Insulin
05:48AM  Pharma Stock Roundup: J&J Back in Talks with Actelion, Teva Settles Corruption Probe
Dec-22-16 10:37AM  Bristol-Myers Squibbs Opdivo May See Strong Demand in 2016
10:22AM  Bristol-Myers, Calithera Team Up for Opdivo/CB-839 Combo
09:06AM  Positive Results from CheckMate-227 Trial May Boost Opdivos Position
07:36AM  Pomalyst Still Dominates the Third-Line Multiple Myeloma Segment
07:36AM  Opdivo Is a Key Growth Driver for Bristol-Myers Squibb in 2016
Dec-21-16 08:42PM  [$$] Business Watch at The Wall Street Journal
06:05PM  Revlimid Continues to Be a Key Growth Driver for Celgene in 2016
04:41PM  BRISTOL MYERS SQUIBB CO Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhib
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. It offers chemically-synthesized drug or small molecule, and biologic in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; immunoscience; cardiovascular; and neuroscience. Its products include Baraclude for the treatment of chronic hepatitis B virus infection; Daklinza and Sunvepra for the treatment of hepatitis C virus infection; Reyataz and Sustiva for the treatment of HIV; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Opdivo, a fully human monoclonal antibody for non-small cell lung and renal cell cancer, and melanoma; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for metastatic melanoma; Abilify, an antipsychotic agent for adults with schizophrenia, bipolar mania disorder, and depressive disorder; Orencia to treat rheumatoid arthritis; and Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation. Its products pipeline includes Beclabuvir, a non-nucleoside NS5B inhibitor for the treatment of HCV; BMS-663068, an investigational compound that is being studied in HIV-1; and Prostvac, a Phase III prostate-specific antigen to treat asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. The company has clinical trial collaborations with Calithera Biosciences, Inc. and Janssen Biotech, Inc.; and a research collaboration with GeneCentric Diagnostics, Inc. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Elicker John ESVP, Public Affairs & IRJan 03Option Exercise0.00950056,232Jan 05 04:37 PM
Bancroft Charles AEVP & Chief Financial OfficerDec 02Option Exercise0.006,4030192,801Dec 06 04:42 PM
Bancroft Charles AEVP & Chief Financial OfficerNov 01Option Exercise0.003,1000187,794Nov 03 05:21 PM
ANDREOTTI LAMBERTODirectorNov 01Option Exercise22.14305,9096,772,825998,777Nov 03 05:22 PM
Elicker John ESVP, Public Affairs & IRNov 01Option Exercise0.00494055,505Nov 03 05:21 PM
ANDREOTTI LAMBERTODirectorOct 11Option Exercise17.51368,7066,456,042692,868Oct 13 05:00 PM
ANDREOTTI LAMBERTODirectorSep 08Sale56.9710,800615,276323,699Sep 09 04:41 PM
ANDREOTTI LAMBERTODirectorSep 07Sale56.7710,800613,116334,499Sep 09 04:41 PM
Nielsen AnneChief Compliance & Ethics OffSep 03Option Exercise0.001,596029,722Sep 07 04:33 PM
ANDREOTTI LAMBERTODirectorAug 25Sale58.9211,600683,472345,299Aug 25 05:10 PM
ANDREOTTI LAMBERTODirectorAug 24Sale59.4311,600689,359356,899Aug 25 05:10 PM
Gordon MurdoEVP, Chief Commercial OfficerAug 01Option Exercise0.001,511015,250Aug 03 04:56 PM
ANDREOTTI LAMBERTODirectorJul 08Sale75.0411,600870,461368,499Jul 11 05:12 PM
ANDREOTTI LAMBERTODirectorJul 07Sale73.8611,600856,776380,099Jul 11 05:12 PM
Blin EmmanuelSVP, Chief Strategy OfficerJul 02Option Exercise0.00951012,516Jul 06 05:58 PM
Cuss Francis MEVP & CSOJul 01Option Exercise0.003,6550291,628Jul 06 05:58 PM
Gordon MurdoEVP, Chief Commercial OfficerJul 01Option Exercise0.002,335014,950Jul 06 05:58 PM
ANDREOTTI LAMBERTODirectorJun 29Sale72.799,800713,342392,194Jun 30 05:42 PM
ANDREOTTI LAMBERTODirectorJun 28Sale71.6713,400960,396390,394Jun 30 05:42 PM
Elicker John ESVP, Public Affairs & IRJun 14Sale72.6911,820859,21955,011Jun 16 04:31 PM
Bancroft Charles AEVP & Chief Financial OfficerMay 20Sale70.7930,2012,137,838184,694May 24 05:04 PM
Caldarella Joseph CSVP & ControllerMay 16Sale72.473,519255,00455,238May 17 04:46 PM
Caforio GiovanniChief Executive OfficerMay 05Option Exercise0.008,0400134,549May 09 04:42 PM
Caforio GiovanniChief Executive OfficerMay 03Option Exercise24.7950,4551,250,602145,958May 05 04:31 PM
Caforio GiovanniChief Executive OfficerMay 03Sale71.3134,5942,466,885117,118May 05 04:31 PM
ANDREOTTI LAMBERTODirectorMay 02Option Exercise26.04234,7206,112,787671,514May 04 05:28 PM
Schmukler Louis SPres., Global Mfg. & SupplyMay 02Sale71.9522,2181,598,65221,971May 04 05:28 PM
ANDREOTTI LAMBERTODirectorMay 02Sale71.88234,72016,870,792436,794May 04 05:28 PM
ANDREOTTI LAMBERTODirectorApr 05Sale66.0011,600765,626436,794Apr 06 04:18 PM
ANDREOTTI LAMBERTODirectorApr 04Sale65.7911,600763,216448,394Apr 06 04:18 PM
JUDGE ANN POWELLSVP, Global Human ResourcesApr 01Option Exercise0.001,554025,260Apr 05 04:59 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 10Option Exercise0.0031,624055,059Mar 14 09:44 PM
Cuss Francis MEVP & CSOMar 10Option Exercise0.0037,1430300,492Mar 14 09:43 PM
ANDREOTTI LAMBERTODirectorMar 10Option Exercise0.00204,4470574,101Mar 14 09:43 PM
Elicker John ESVP, Public Affairs & IRMar 10Option Exercise0.0020,860074,177Mar 14 09:43 PM
Caldarella Joseph CSVP & ControllerMar 10Option Exercise0.0020,460067,864Mar 14 09:44 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 10Option Exercise0.0031,406089,478Mar 14 09:42 PM
Caforio GiovanniChief Executive OfficerMar 10Option Exercise0.0060,6230132,906Mar 14 09:42 PM
LEUNG SANDRAEVP, General CounselMar 10Option Exercise0.0057,4840366,730Mar 14 09:42 PM
JUDGE ANN POWELLSVP, Global Human ResourcesMar 10Option Exercise0.0025,435032,069Mar 14 09:43 PM
Nielsen AnneChief Compliance & Ethics OffMar 10Option Exercise0.008,806059,091Mar 14 09:41 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 10Option Exercise0.0075,6180247,158Mar 14 09:41 PM
Blin EmmanuelSVP, Head of CommercializationMar 10Option Exercise0.0011,707013,498Mar 14 09:42 PM
Gordon MurdoSVP, Head of Worldwide MarketsMar 10Option Exercise0.0019,309019,608Mar 14 09:41 PM
CAMPBELL LEWIS BDirectorMar 08Option Exercise24.962,50062,4002,500Mar 10 04:36 PM
CAMPBELL LEWIS BDirectorMar 08Sale66.002,500165,0000Mar 10 04:36 PM
Caforio GiovanniChief Executive OfficerMar 06Option Exercise0.002,889079,627Mar 08 04:42 PM
Gordon MurdoSVP, Head of Worldwide MarketsMar 06Option Exercise0.001,28202,611Mar 08 04:43 PM
Nielsen AnneChief Compliance & Ethics OffMar 06Option Exercise0.00724050,821Mar 08 04:43 PM
Caldarella Joseph CSVP & ControllerMar 06Option Exercise0.001,931048,253Mar 08 04:43 PM
LEUNG SANDRAEVP, General CounselMar 06Option Exercise0.005,5740315,121Mar 08 04:41 PM
Elicker John ESVP, Public Affairs & IRMar 06Option Exercise0.001,043053,715Mar 08 04:41 PM
Cuss Francis MEVP & CSOMar 06Option Exercise0.003,0100269,043Mar 08 04:42 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 06Option Exercise0.002,391060,032Mar 08 04:40 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 06Option Exercise0.007,3240169,885Mar 08 04:40 PM
Blin EmmanuelSVP, Head of CommercializationMar 06Option Exercise0.0081901,553Mar 08 04:41 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 06Option Exercise0.002,528024,746Mar 08 04:40 PM
Caldarella Joseph CSVP & ControllerMar 04Sale64.6412,962837,91646,322Mar 07 05:41 PM
Caforio GiovanniChief Executive OfficerFeb 17Option Exercise22.8920,125460,66188,778Feb 19 04:32 PM
LEUNG SANDRAEVP, General CounselFeb 17Option Exercise22.7314,560330,949319,699Feb 19 04:32 PM
LEUNG SANDRAEVP, General CounselFeb 17Sale63.5710,152645,342309,547Feb 19 04:32 PM
Caforio GiovanniChief Executive OfficerFeb 17Sale63.5812,040765,52776,738Feb 19 04:32 PM
ANDREOTTI LAMBERTODirectorFeb 04Option Exercise0.00148,1800445,820Feb 08 04:31 PM
Paliwal Dinesh CDirectorFeb 01Option Exercise0.003,25703,257Feb 03 06:28 PM